These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 18538554)

  • 21. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age.
    Harper DM
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S11-7. PubMed ID: 18649932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women.
    Shiko Y; Konno R; Konishi H; Sauvaget C; Ohashi Y; Kakizoe T
    BMC Infect Dis; 2020 Nov; 20(1):808. PubMed ID: 33153446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.
    Cuzick J; Castañón A; Sasieni P
    Br J Cancer; 2010 Mar; 102(5):933-9. PubMed ID: 20104226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
    Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A;
    J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [HPV vaccination and cervical cancer screening].
    Sigurdsson K
    Laeknabladid; 2007 Dec; 93(12):819, 821. PubMed ID: 18057470
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
    Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
    Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage.
    Brotherton JML; Bloem PN
    Best Pract Res Clin Obstet Gynaecol; 2018 Feb; 47():42-58. PubMed ID: 28986092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
    Paavonen J; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter D; Kitchener H; Castellsague X; Teixeira JC; Skinner SR; Hedrick J; Jaisamrarn U; Limson G; Garland S; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Jenkins D; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Lancet; 2009 Jul; 374(9686):301-14. PubMed ID: 19586656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic HPV vaccination: a major breakthrough in the fight against cervical cancer?
    Saleem A; Tristram A; Fiander A; Hibbitts S
    Minerva Med; 2009 Dec; 100(6):503-23. PubMed ID: 20010484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.
    Usher C; Tilson L; Olsen J; Jepsen M; Walsh C; Barry M
    Vaccine; 2008 Oct; 26(44):5654-61. PubMed ID: 18723068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
    Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
    McKeage K; Romanowski B
    Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cervical cancer prevention: the impact of HPV vaccination].
    Monsonégo J
    Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in cervical cancer screening and human papillomavirus vaccines.
    Feeley C
    J Br Menopause Soc; 2006 Mar; 12(1):19-23. PubMed ID: 16513018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials.
    Arbyn M; Xu L
    Expert Rev Vaccines; 2018 Dec; 17(12):1085-1091. PubMed ID: 30495978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
    Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
    Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
    Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
    Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
    Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
    Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HPV vaccines: are they the answer?
    Stanley M
    Br Med Bull; 2008; 88(1):59-74. PubMed ID: 18940889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.